Key Finding
Linaclotide 290 mcg daily was most effective for improving abdominal pain and bowel movement frequency in IBS-C, but higher doses of both linaclotide and tenapanor were associated with increased adverse events compared to lower doses.
Researchers analyzed 16 studies involving over 1,000 patients to compare medications used for irritable bowel syndrome with constipation (IBS-C). They examined drugs called intestinal secretagogues and prokinetic agents, which help move stool through the intestines. The study found that higher doses of linaclotide (290 mcg daily) and tenapanor (50 mg twice daily) were most effective at relieving abdominal pain and increasing bowel movements compared to placebo. However, these higher doses also caused more side effects than lower doses or placebo. This research is important because it provides the first comprehensive comparison of these medications at different doses, helping doctors understand which treatments work best. For patients with IBS-C considering their treatment options, this study highlights that while medications can provide symptom relief, they come with trade-offs between effectiveness and side effects. Many patients with IBS-C explore complementary approaches like acupuncture alongside conventional treatments. Acupuncture may help address digestive symptoms by regulating gut motility and reducing visceral pain sensitivity through effects on the nervous system. Some patients find that combining acupuncture with dietary modifications and stress management provides a more holistic approach to managing IBS-C symptoms with potentially fewer side effects than higher-dose medications alone. If you're interested in exploring acupuncture for IBS-C, seek care from a licensed acupuncturist with experience treating digestive disorders.
This network meta-analysis evaluated 16 randomized controlled trials examining intestinal secretagogues and prokinetic agents for IBS-C treatment through November 2024. The study included five drugs at various dosing regimens, providing the first indirect head-to-head comparison of these agents. Key findings indicate linaclotide 290 mcg daily demonstrated superior efficacy for abdominal pain relief and increased bowel movement frequency compared to placebo. Tenapanor 50 mg twice daily also showed effectiveness for pain management. However, dose-response analysis revealed higher doses (linaclotide 125-290 mcg daily, tenapanor 50 mg bid) were associated with significantly increased adverse event incidence compared to lower doses and placebo. Clinical implications: While higher-dose secretagogues provide enhanced symptom control, practitioners should carefully weigh efficacy against safety profiles when prescribing. This data supports integrative approaches combining conventional pharmacotherapy with acupuncture, which may modulate visceral hypersensitivity and gut motility through neuroendocrine pathways, potentially allowing for lower medication doses.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.